Barclays lowered the firm’s price target on Insulet to $214 from $257 and keeps an Equal Weight rating on the shares. The firm made a number of changes to its model, reflecting the company’s full year expectations and preliminary comments on 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PODD:
- Early notable gainers among liquid option names on November 6th
- Early notable gainers among liquid option names on November 3rd
- Insulet price target lowered to $240 from $330 at Wells Fargo
- Insulet price target lowered to $175 from $355 at Canaccord
- Insulet price target lowered to $180 from $219 at Baird
